

REMARKS

This paper is being filed in response to the Office Communication dated June 18, 2002. Applicants enclose herewith a Sequence Listing in paper and computer-readable form.

Claims 1-28 are pending. Claim 10 has been amended. A rewritten paragraph appears in the preceding "IN THE SPECIFICATION" section. A rewritten claim appears in the preceding "IN THE CLAIMS" section. Attached hereto is a marked-up version of the changes made by the instant amendment captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE" and is included pursuant to 37 C.F.R. §1.121(c)(ii). Should any discrepancies be discovered, the version presented in the preceding "IN THE SPECIFICATION" and "IN THE CLAIMS" sections shall take precedence.

Amended claim 10 is fully supported by the application as filed, *inter alia*, original claim 10 and original paragraph [0018].

A Sequence Listing has not previously been filed for the instant application. Applicants submit herewith a Sequence Listing in paper and computer readable form. I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e), are the same. I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(g), herein does not include new matter.

Support for the sequences listed in the Sequence Listing may be found in the specification as filed, *inter alia*, at paragraph [0018].


Applicants do not believe that any fees are required with this Response.

Nevertheless, the Commission is authorized to charge any required fees not otherwise enclosed herewith to Deposit Account No. 02-4377. Two copies of this page are enclosed.

Applicants enclose a copy of the Notice to Comply herewith.

Respectfully submitted,

July 17, 2002



Gary Abelev
PTO Reg. No. 40,479

Attorney for Applicants
BAKER BOTTS, L.L.P.
30 Rockefeller Plaza
New York, NY 10112
(212) 408-2522

Enclosures

VERSION WITH MARKINGS TO SHOW CHANGES MADE

This marked-up version was prepared with DeltaView software (v2.5.163). In this section, added text is marked with double underlining. *e.g.* added text, and deleted text is marked by a single strikethrough, *e.g.* ~~deleted text~~.

IN THE SPECIFICATION

Paragraph [0018] has been **amended** as follows:

[0018] The accompanying figures illustrate the present invention. Abbreviations are used as follows:

P1[°] H-Lys-Phe-Met-Met-Thr-Pro-pTyr-Val-Val-Thr-Arg-NH₂ (SEQ ID NO:1)

P1* H-Lys-Phe-Met-Met-pThr-Pro-Tyr-Val-Val-Thr-Arg-NH₂ (SEQ ID NO:2)

P1*° H-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH₂ (SEQ ID NO:3)

TAMRA-P1*° 5-TAMRA-AEEA-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH₂ (SEQ ID NO:4)

TAMRA 5'-(6-carboxytetramethylrhodamine)

AEEA 8-amino-3,6-dioxaoctanoic acid linker

IN THE CLAIMS

Claim 10 has been **amended** as follows:

10. (AMENDED) The process according to claim 9, wherein the ligand comprises Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH₂, and particular is 5-Tamra-~~Arg~~TAMRA-AEEA-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH₂.